ArticleJournal of medicinal chemistry2014
Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).
Article in Journal of medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 163 citations in OpenAlex.
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications.Chemical reviews · 2025Review
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics.Nuclear medicine and molecular imaging · 2025Review
- CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Efficacy of Various Complexing Agents for Displacing Biologically Important Ligands from Eu(III) and Cm(III) Complexes in Artificial Body Fluids-An In Vitro Decorporation Study.International journal of molecular sciences · 2025Article
- [ACS omega · 2025Article
- Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.Pharmaceutics · 2024Review
- Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications.EJNMMI radiopharmacy and chemistry · 2024Article
- Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Sc-HOPO: A Potential Construct for Use in Radioscandium-Based Radiopharmaceuticals.Inorganic chemistry · 2023Article
- Evaluation ofACS omega · 2023Article
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Radiometal chelators for infection diagnostics.Frontiers in nuclear medicine · 2023Article
- Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, andACS omega · 2022Article
- Synthesis and evaluation of Diaza-Crown Ether-Backboned chelator containing hydroxamate groups for Zr-89 chelation chemistry.Bioorganic & medicinal chemistry letters · 2022Article
- CoreNanoscale advances · 2022Article
- PET Imaging of Acidic Tumor Environment WithFrontiers in oncology · 2022Article
- Review
- Side-by-Side Comparison of Five Chelators forCancers · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chelator for (89)Zr(4+); however, accumulation of (89)Zr in the bones of mice suggests that (89)Zr(4+) is released from DFO in vivo. An improved chelator for (89)Zr(4+) could eliminate the release of osteophilic (89)Zr(4+) and lead to a safer PET tracer with reduced background radiation dose. Herein, we present an octadentate chelator 3,4,3-(LI-1,2-HOPO) (or HOPO) as a potentially superior alternative to DFO. The HOPO ligand formed a 1:1 Zr-HOPO complex that was evaluated experimentally and theoretically. The stability of (89)Zr-HOPO matched or surpassed that of (89)Zr-DFO in every experiment. In healthy mice, (89)Zr-HOPO cleared the body rapidly with no signs of demetalation. Ultimately, HOPO has the potential to replace DFO as the chelator of choice for (89)Zr-based PET imaging agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.